Tradestie Institutional Equity Comparison Engine

MLTX vs ARVN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MLTX Overall Edge

MLTX Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ARVN counters with relative strength in Valuation. Fundamentally, MLTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ARVN at 17.9x Forward P/E and -10.1% operating margin (-98.8% YoY). In options structure, MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against ARVN sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ARVN
MLTX N/M vs ARVN 17.9x Fwd P/E
Growth & Margin Winner MLTX
Op Margin 0.0% vs -10.1% ยท YoY +0.0% vs -98.8%
Momentum & Technical Winner MLTX
1Y -5.7% vs -33.4% ยท 52W Pos 17% vs 5%
Options & Structure Winner MLTX
BREAKDOWN (7th %ile IV) vs BREAKDOWN (25th %ile IV)
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
1M Return +24.08%
1Y Return -5.65%
Forward P/E N/M
Unified AI Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
ARVN NASDAQ
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
1M Return -3.3%
1Y Return -33.4%
Forward P/E 17.9x
Unified AI Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MLTX -5.65% ARVN -33.4% Spread: +27.75 pp (MLTX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MLTX TTM Op. Margin: 0.0% ARVN TTM Op. Margin: -10.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs ARVN. Trailing 12-month operating profitability (MLTX 0.0% vs ARVN -10.1%) and valuation multiples (MLTX N/M vs ARVN 17.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MLTX (5) vs ARVN (5)
Institutional Metric MLTX ARVN Criterion Row Winner
Market Capitalization Scale $1.1B $449.9M Larger Scale MLTX
Trailing P/E Ratio Valuation N/M 17.9x Lower Multiple ARVN
Forward P/E Ratio Valuation N/M 17.9x Lower Multiple ARVN
Revenue Growth (YoY) Growth +0.0% -98.8% Higher Growth MLTX
Operating Margin (TTM) Profitability 0.0% -10.1% Higher Margin MLTX
Net Profit Margin Profitability 0.0% -3.5% Higher Margin MLTX
Return on Equity (ROE) Capital Efficiency -81.5% -1.8% Higher ROE ARVN
52-Week Range Position Momentum 17% ($9โ€“$23) 5% ($6โ€“$15) Stronger Trend MLTX
Beta / 30D Volatility Risk Regime 1.61ฮฒ ยท 90% Vol 1.40ฮฒ ยท 66% Vol Lower Realized Risk ARVN
Unified Institutional Score Composite Signal 38.3 / 100 (SELL) 52.9 / 100 (HOLD) Higher Composite ARVN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MLTX vs ARVN Buy Guide
MLTX BREAKDOWN
103d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live MLTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ARVN BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ARVN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MLTX nor ARVN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.